Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G
A phase 2/3 trial of Adagrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Mirati Therapeutics Inc., now recruiting.
Overview
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 is a phase 2/3 interventional study registered as NCT04613596 by Mirati Therapeutics Inc., with 626 participants planned, started 2020-12-02 and due to reach its primary completion in 2028-10-31. Interventions recorded: Adagrasib, Adagrasib, Adagrasib, Adagrasib, Pembrolizumab. Conditions listed: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and P
Shares Bristol Myers Squibb, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialCombination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation
Shares Adagrasib, Bristol Myers Squibb, Pembrolizumab, Non-small-cell lung cancer.
- TrialA Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Shares Adagrasib, Bristol Myers Squibb, Pembrolizumab, Non-small-cell lung cancer.
- TrialTrial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Shares Adagrasib, Bristol Myers Squibb.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Bristol Myers Squibb, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
- TrialA Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell
Shares Bristol Myers Squibb, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advance
Shares Bristol Myers Squibb, Pembrolizumab, Small-cell lung cancer, Non-small-cell lung cancer.